Lumito AB Quarterly Report (1 Jan to 31 March) 2021
Significant events during the first quarter of 2021 Lumito’s advisors in the field of pathology have had the opportunity to review the company’s UCNP immunostaining of invasive breast cancer with an antibody against HER2 (the target molecule) at a high image resolution. “The signals are uniquely sharp and clear, which gives the impression of staining […]
Lumito publishes Year-end Report for 2020
Financial overview 2020 Financial overview of the fourth quarter, 1 October – 31 December 2020. Net sales amounted to kSEK 0 (0). Result after taxes amounted to kSEK -5,200 (-2,545). Basic and diluted earnings per share amounted to SEK -0.06 (-0.04) Cash flow from operating activities amounted to kSEK -5,198 (-3,145). Financial overview of the […]
Quarterly report 3, 2020, Lumito AB (publ)
Financial overview of the third quarter July 1st – September 30th, 2020 Net sales amounted to SEK 0 (0) thousand. Profit after tax amounted to SEK -3,851 (-1,325) thousand. Earnings per share before and after dilution amounted to SEK -0.05 (-0.02). Cash flow from operating activities amounted to SEK -3,850 (-1,325) thousand. Nine months, January […]
Quarterly report 1, 2020, Lumito AB (publ).
Financial overview of the first quarter, 1 January – 31 March 2020 Result after taxes amounted to kSEK -2,795 (-1,958). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -2,793 (-1,958). Cash and cash equivalents amounted to kSEK 17,675 (8,079) on the balance sheet date. […]
Lumito AB Quarterly Report (1 October to 31 December) 2019
Financial overview of the fourth quarter, 1 October – 31 December 2019 Result after taxes amounted to kSEK -2,545 (-2,148). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -3,145 (-2,148). Financial overview of the year as a whole, 1 January – 31 December […]